FIG 2.

Pharmacodynamics of ciprofloxacin against Escherichia coli ATCC 25922 (a), Pseudomonas aeruginosa ATCC 27853 (b), Acinetobacter baumannii ATCC 19606 (c), and Klebsiella pneumoniae ATCC 13883 (d) at human-equivalent rat doses in the rat neutropenic thigh infection model following i.v. infusions (see Materials and Methods for details). The AUC/MIC ratio for each treatment is indicated above the corresponding bar. Error bars represent the mean and standard deviation. Asterisks indicate significant differences compared to the 2-h infection control (P < 0.05). LOQ, limit of quantitation.